Taofeek K Owonikoko1, Suzanne E Dahlberg2, Saad A Khan3, David E Gerber3, Jonathan Dowell3, Rebecca A Moss4, Chandra P Belani5, Christine L Hann6, Charu Aggarwal7, Suresh S Ramalingam8. 1. The Winship Cancer Institute of Emory University, Atlanta, GA, United States. Electronic address: towonik@emory.edu. 2. Dana-Farber Cancer Institute, Boston, MA, United States. 3. University of Texas Southwestern Medical Center, Dallas, TX, United States. 4. Rutgers Cancer Institute of New Jersey and Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08903-2681, United States. 5. Penn State Hershey Cancer Institute, Hershey, PA, United States. 6. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States. 7. Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, United States. 8. The Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Abstract
OBJECTIVES: Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. MATERIALS AND METHODS: The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75 mg/m(2) on day 1) and E (100mg/m(2) on days 1-3) in a 21-day cycle. The starting dose of V was 60 mg (bid days 1-7) with plan to escalate to 100mg (days 1-7) or de-escalate to 40 mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naïve, extensive stage SCLC were included. RESULTS: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60 mg (DLT in 0 of 3 patients) and 100mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. CONCLUSIONS: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLC patients.
OBJECTIVES:Veliparib (V) potentiated therapeutic efficacy of cisplatin (C) and etoposide (E) in preclinical models of SCLC. We conducted this phase 1 study to establish the safety of the combination in human subjects. MATERIALS AND METHODS: The study employed the 3+3 dose escalation design to establish the safety and recommended phase 2 dose (RP2D) of V when combined with fixed doses of C (75 mg/m(2) on day 1) and E (100mg/m(2) on days 1-3) in a 21-day cycle. The starting dose of V was 60 mg (bid days 1-7) with plan to escalate to 100mg (days 1-7) or de-escalate to 40 mg (days 1-7) depending on the dose limiting toxicity (DLT) experience during cycle 1. Patients with treatment-naïve, extensive stage SCLC were included. RESULTS: The study enrolled 9 patients: M/F (4/5); median age (60); White/African American (8/1). V was tolerated at the 60 mg (DLT in 0 of 3 patients) and 100mg dose (DLT in 1 of 6 patients; grade 5 cardiac failure). Veliparib at 100mg in combination with standard doses of C and E was established as the RP2D. Grades 3-5 adverse events irrespective of attribution during cycle 1 included: dehydration (1), diarrhea (1), fatigue (1), febrile neutropenia (1), heart failure (1), leukopenia (6), lymphopenia (1), nausea (2), neutropenia (8), respiratory failure (1), and thrombocytopenia (2). Investigator-assessed efficacy outcome in 7 evaluable patients were stable disease in 2/7 (28.6%), partial response in 4/7 (57.1%), and complete response in 1/7 (14.3%) patients. CONCLUSIONS: This study demonstrated the safety of combining veliparib with cisplatin and etoposide in previously untreated SCLCpatients.
Authors: M S Aapro; J Bohlius; D A Cameron; Lissandra Dal Lago; J Peter Donnelly; N Kearney; G H Lyman; R Pettengell; V C Tjan-Heijnen; J Walewski; Damien C Weber; C Zielinski Journal: Eur J Cancer Date: 2010-11-20 Impact factor: 9.162
Authors: Channing J Paller; Penelope A Bradbury; S Percy Ivy; Lesley Seymour; Patricia M LoRusso; Laurence Baker; Larry Rubinstein; Erich Huang; Deborah Collyar; Susan Groshen; Steven Reeves; Lee M Ellis; Daniel J Sargent; Gary L Rosner; Michael L LeBlanc; Mark J Ratain Journal: Clin Cancer Res Date: 2014-08-15 Impact factor: 12.531
Authors: Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544
Authors: Jack M Su; Patrick Thompson; Adekunle Adesina; Xiao-Nan Li; Lindsay Kilburn; Arzu Onar-Thomas; Mehmet Kocak; Brenda Chyla; Evelyn McKeegan; Katherine E Warren; Stewart Goldman; Ian F Pollack; Maryam Fouladi; Alice Chen; Vincent Giranda; James Boyett; Larry Kun; Susan M Blaney Journal: Neuro Oncol Date: 2014-06-07 Impact factor: 12.300
Authors: Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Taofeek K Owonikoko; Guojing Zhang; Xingming Deng; Michael R Rossi; Jeffrey M Switchenko; Gregory H Doho; Zhengjia Chen; Sungjin Kim; Sandy Strychor; Susan M Christner; Jan Beumer; Chunyang Li; Ping Yue; Alice Chen; Gabriel L Sica; Suresh S Ramalingam; Jeanne Kowalski; Fadlo R Khuri; Shi-Yong Sun Journal: Cancer Med Date: 2014-08-13 Impact factor: 4.452
Authors: Paul A Bunn; John D Minna; Alexander Augustyn; Adi F Gazdar; Youcef Ouadah; Mark A Krasnow; Anton Berns; Elisabeth Brambilla; Natasha Rekhtman; Pierre P Massion; Matthew Niederst; Martin Peifer; Jun Yokota; Ramaswamy Govindan; John T Poirier; Lauren A Byers; Murry W Wynes; David G McFadden; David MacPherson; Christine L Hann; Anna F Farago; Caroline Dive; Beverly A Teicher; Craig D Peacock; Jane E Johnson; Melanie H Cobb; Hans-Guido Wendel; David Spigel; Julien Sage; Ping Yang; M Catherine Pietanza; Lee M Krug; John Heymach; Peter Ujhazy; Caicun Zhou; Koichi Goto; Afshin Dowlati; Camilla Laulund Christensen; Keunchil Park; Lawrence H Einhorn; Martin J Edelman; Giuseppe Giaccone; David E Gerber; Ravi Salgia; Taofeek Owonikoko; Shakun Malik; Niki Karachaliou; David R Gandara; Ben J Slotman; Fiona Blackhall; Glenwood Goss; Roman Thomas; Charles M Rudin; Fred R Hirsch Journal: J Thorac Oncol Date: 2016-01-30 Impact factor: 15.609
Authors: Chandra P Belani; Suzanne E Dahlberg; Charles M Rudin; Martin Fleisher; Helen X Chen; Naoko Takebe; Mario R Velasco; William J Tester; Keren Sturtz; Christine L Hann; James C Shanks; Manish Monga; Suresh S Ramalingam; Joan H Schiller Journal: Cancer Date: 2016-05-10 Impact factor: 6.860
Authors: Mariacarmela Santarpia; Maria Grazia Daffinà; Niki Karachaliou; Maria González-Cao; Chiara Lazzari; Giuseppe Altavilla; Rafael Rosell Journal: Transl Lung Cancer Res Date: 2016-02
Authors: Taofeek K Owonikoko; Suzanne E Dahlberg; Gabriel L Sica; Lynne I Wagner; James L Wade; Gordan Srkalovic; Bradley W Lash; Joseph W Leach; Ticiana B Leal; Charu Aggarwal; Suresh S Ramalingam Journal: J Clin Oncol Date: 2018-12-05 Impact factor: 44.544
Authors: P H Thaker; R Salani; W E Brady; H A Lankes; D E Cohn; D G Mutch; R S Mannel; K M Bell-McGuinn; P A Di Silvestro; D Jelovac; J S Carter; W Duan; K E Resnick; D S Dizon; C Aghajanian; P M Fracasso Journal: Ann Oncol Date: 2017-03-01 Impact factor: 32.976